Isn't that interesting. You say you are Layton and you own
Isn't that interesting. You say you are Layton and you own no shares and you know all about the last 17 years. Who cares what you do or do not know ?? There is nothing you can do or say that will change anything here. Many of these people have been here less than a year. As for me and my years here I loved every minute of it because when the plan comes together as it has and these pigs have zero ways out I feel really good. Many of the people don't have that much because they work hard and have families.
They are going to have all there is In life to have and it gets closer each day. People like your self will one day find out what happened here.
You can laugh and have your fun but be very careful.
HOLD EVERY SHARE YOU OWN.
Telvue Corp (TEVE) Stock Research Links
Holding TelVue shares has made it the billion dollar bomb shell it is.
There is no limit to the loss of someone has been caught in a short squeeze.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...
Continue Reading
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Top 5 Most Recently Viewed Articles
Sonic Teams Up with Obsessed Garage to Transform Home Garages Sonic, a front-runner in delivering high-quality tool solutions and equipment, has recently announced an exciting partnership with Obsessed Garage. This collaboration aims to cater to home garage enthusiasts who demand tools and storage solutions that match the quality standards utilized by professionals in the...
Continue Reading
Important Update for Sun Communities, Inc. Investors There is a significant call to action for investors of Sun Communities, Inc. as a class action lawsuit has been filed against the company, urging those affected to act promptly. This is a crucial moment for investors who purchased securities from the company during a specific period. Legal representation is being...
Continue Reading
XOMA Stock Performance Overview XOMA Ltd's stock has recently made headlines by reaching a remarkable 52-week high, with shares trading at an impressive $30.49. This achievement not only signifies a significant milestone for the company but also highlights a robust year-over-year growth that can't be overlooked. Investors have observed a substantial increase of 73.82% in...
Continue Reading
Evolv Technologies Faces Turmoil with Executive Departures Evolv Technologies Holdings (NASDAQ: EVLV) is navigating turbulent times following the resignation of its Chief Financial Officer, Mark Donohue. His departure comes amid serious allegations of improper revenue recognition practices that have raised questions about the company's integrity and financial health....
Continue Reading
Editas Medicine Maintains Price Target Amidst Financial Developments Recently, Leerink Partners reaffirmed a Market Perform rating for Editas Medicine (NASDAQ: EDIT), keeping a price target steady at $8.00. This decision comes closely after the company announced a substantial financing agreement with DRI Healthcare Trust. Under this agreement, Editas is set to receive an...
Continue Reading